Tempus AI shares fall on $1.5bn Personalis deal
Tempus AI is buying cancer-test developer Personalis for $1.5bn to expand in the growing minimal residual disease market, but investors punished the deal over profitability concerns.
Tempus AI has agreed to purchase Personalis for $1.5bn in an all-stock transaction, though it retains an option to pay up to half the consideration in cash. The deal assigns a price of $16.25 per share to the California-based company, representing a 6% premium over Personalis' closing price on July 17.
Equity markets responded harshly to the news ahead of the July 20 open. Tempus shares declined 7.74% to $48.41, reducing its market capitalisation to $8.69bn. Personalis stock fared even worse, plummeting 13.2% to finish the session at $13.34, well below the proposed acquisition price.
The negative reception appears rooted in the target's financial profile. William Blair analysts pointed to Personalis' loss-making operations as a potential source of investor hesitation, warning that the acquisition will test Tempus' path to profitability. Preliminary second-quarter figures showed Personalis generated $22.4m in revenue.
However, the underlying business is scaling quickly. Personalis distributed 10,384 minimal residual disease (MRD) tests during the quarter, a 33% increase in volume compared to the prior three months. MRD testing, which identifies lingering cancer cells post-treatment, is a rapidly expanding niche within precision oncology.
Tempus and Personalis have been jointly developing and commercialising the NeXT Personal MRD test since November 2023. Tempus CEO Eric Lefkofsky framed the acquisition as a way to lock down a critical growth area. "MRD is a large and rapidly growing market with the potential to truly transform how cancer patients are monitored, helping clinicians make faster and more informed decisions when cancer recurs," he said.
Lefkofsky noted that combining Personalis' highly sensitive technology with Tempus' commercial infrastructure positions the companies to capture rising clinical adoption and reimbursement momentum. For Personalis CEO Chris Hall, the tie-up offers necessary scale. "Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians and biopharma partners," Hall said.
The $1.5bn purchase price accounts for Tempus' existing 12.25% stake in Personalis. The transaction is slated to close by early 2027.
